Facial Hyperpigmentation Clinical Trial
Official title:
Efficacy and Tolerability of an Isobutylamido-thiazolyl-resorcinol Cream 0.2% for Facial Hyperpigmentation, A Randomized Double-blind and Vehicle-Controlled Study
| Verified date | March 2022 |
| Source | Institute of Dermatology, Thailand |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
Facial hyperpigmentation is a common skin issue that can cause embarrassment and affect the quality of life in majority of people. The investigators are conducting a research to study an efficacy and tolerability of Isobutylamido-thiazolyl-resorcinol 0.2% in lightening of the facial hyperpigmentation in comparison to vehicle intervention in 4, 8 and 12-week period. The ultimate goal is to provide the best cosmetic cream to improve the quality of life of people who suffer from facial hyperpigmentation.
| Status | Completed |
| Enrollment | 200 |
| Est. completion date | January 31, 2021 |
| Est. primary completion date | November 30, 2020 |
| Accepts healthy volunteers | Accepts Healthy Volunteers |
| Gender | All |
| Age group | 18 Years and older |
| Eligibility | Inclusion Criteria: 1. Subjects are Thai adults age 18 years old and above . 2. Subjects suffer from facial hyperpigmentation for at least 10 years, with or without freckles, lentigo or dark sports. 3. Subjects must be able to attend monthly sessions in the period of 12 weeks session. 4. Subjects must refrain from using other whitening cream such as hydroquinone, azelaic acid, kojic acid, arbutin, glycolic acid or any other creams which whiten the skin including chemical peel or whitening pills such as Tranexamic acid at least 1 month before the trial. 5. Subjects must refrain from receiving both ablative and nonablative laser treatment at least 3 months before the trial. 6. Subjects who can apply sun screen with UVA and UVB protection that has a minimum of SPF30 daily. Exclusion Criteria: 1. Subjects who have conditions such as Lichen planus pigmentosus, Pigmented contact dermatitis, Photosensitivity, Ashy dermatosis, Dermal melanosis, e.g. Nevus of Hori, Nevus of Ota, Dermal melanocyte hamartoma 2. Subjects with a congenital disease which darkens skin tone, e.g. Addison's disease, Cushing's syndrome and Thyrotoxicosis 3. Subjects with a congenital or serious disease with unpredictable symptoms such as Cirrhosis, cardiovascular diseases, Neurological diseases, gastrointestinal disease, Reproductive system diseases, Cancer and Psychiatric diseases. 4. Subjects who take pills that might cause hyperpigmentation such as chemotherapy, Amiodarone, Chlorpromazine, Hydroxychloroquine, Gold, Birth control pills (if related to causing hyperpigmentation issue) 5. Female subjects with pregnancy and breastfeeding. 6. Subjects who are allergic to chemical compound in the cream such as Alcohol denat, Phenoxyethanol or fragrance. |
| Country | Name | City | State |
|---|---|---|---|
| Thailand | Institute of Dermatology | Ratchathewi | Bangkok |
| Lead Sponsor | Collaborator |
|---|---|
| Institute of Dermatology, Thailand | Beiersdorf (Thailand) Co., Ltd. |
Thailand,
Briganti S, Camera E, Picardo M. Chemical and instrumental approaches to treat hyperpigmentation. Pigment Cell Res. 2003 Apr;16(2):101-10. Review. — View Citation
Espín JC, Varón R, Fenoll LG, Gilabert MA, García-Ruíz PA, Tudela J, García-Cánovas F. Kinetic characterization of the substrate specificity and mechanism of mushroom tyrosinase. Eur J Biochem. 2000 Mar;267(5):1270-9. — View Citation
Lacz NL, Vafaie J, Kihiczak NI, Schwartz RA. Postinflammatory hyperpigmentation: a common but troubling condition. Int J Dermatol. 2004 May;43(5):362-5. Review. — View Citation
Mann T, Gerwat W, Batzer J, Eggers K, Scherner C, Wenck H, Stäb F, Hearing VJ, Röhm KH, Kolbe L. Inhibition of Human Tyrosinase Requires Molecular Motifs Distinctively Different from Mushroom Tyrosinase. J Invest Dermatol. 2018 Jul;138(7):1601-1608. doi: 10.1016/j.jid.2018.01.019. Epub 2018 Feb 7. — View Citation
Ortonne JP, Pandya AG, Lui H, Hexsel D. Treatment of solar lentigines. J Am Acad Dermatol. 2006 May;54(5 Suppl 2):S262-71. Review. — View Citation
Rossi AM, Perez MI. Treatment of hyperpigmentation. Facial Plast Surg Clin North Am. 2011 May;19(2):313-24. doi: 10.1016/j.fsc.2011.05.010. — View Citation
Weatherall IL, Coombs BD. Skin color measurements in terms of CIELAB color space values. J Invest Dermatol. 1992 Oct;99(4):468-73. — View Citation
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Color assessment of facial hyperpigmentation by Color Analysis program will be evaluated every visit. | Each visit, photos are taken on all patients by VISIA-CR system camera on 3 positions of the face, straight and 37* on both sides with standard unfiltered and cross polarized lens. Each time the photos are filed and the colors are analyzed in order to be compared the changes between visits. | 12 weeks | |
| Primary | Physician's Global Assessment of facial hyperpigmentation will be evaluated every visit. | Evaluate the changes of facial hyperpigmentation by global assessment score: 0=Completely clear,1=Almost clear, 2=Marked improved, 3=Moderate improved, 4=Slight improved, 5=No change, 6=Worse | 12 weeks | |
| Primary | Patient's Global Assessment of facial hyperpigmentation will be evaluated every visit. | Evaluate the changes of facial hyperpigmentation by global assessment score: 0=Completely clear,1=Almost clear, 2=Marked improved, 3=Moderate improved, 4=Slight improved, 5=No change, 6=Worse | 12 weeks | |
| Primary | Patient's Self-Grading of facial hyperpigmentation will be evaluated every visit. | Visual self-grading by patients from 1 to 10 by 1 is the least and 10 is the most in the criteria of evenness, spots and skin clarity | 12 weeks | |
| Primary | Evaluate side effects of Isobutylamido-thiazolyl-resorcinol cream 0.2% or vehicle cream every visit. | All patients are asked about the side effects of using the cream such as eczema, hypopigmentation, and redness. | 12 weeks |